Why Attend?
Animal Health, Nutrition and Technology Innovation Europe is the sector’s premier innovation summit, showcasing the most exciting emerging companies and connecting them with investors and strategic partners.
Our mission is to engage all key participants in the value chain so we can address the full scope of how animal health impacts pet owners, veterinarians, and farmers today.
We would be delighted for you to join us as we address the challenges and opportunities for innovation in our ever-evolving industry.
Innovation Showcase
The Innovation Showcase will return in 2024.
The showcase is a unique opportunity for emerging companies with amazing technology to present in front of the industry’s most influential figures and investors.
We'll be opening 2024 applications soon so make sure you check back in!
2023 Speakers
Kristin Peck
Jeff Simmons
Robert Kelly
Laetitia Cicchelero
Matt Dobbs
Simon Doherty
Vinicius Chiappetta
Dave Ross
Jamie Brannan
Mariama Boumanjal
Julia Stephanus
Julia Stephanus is a 30 year veteran of the veterinary pharmaceutical industry. Currently Julia is President of Avviare, a consulting firm specializing in supporting veterinary focused start-ups.
Julia has been involved in the development and launch of 28 veterinary products. She has been a senior executive in two start-up pharmaceutical companies (Aratana Therapeutics and Summit VetPharm), and held key positions at multi-nationals including Pfizer (now Zoetis) and its legacy companies.
As Chief Commercial Officer of Aratana Julia provided the commercial leadership resulting in a successful IPO (NASDAQ:PETX), high-impact corporate branding, innovative go-to-market strategies for five therapeutics and the staffing of the inaugural commercial organization.
As founder and CEO of Summit VetPharm, Julia developed and launched a new line of companion animal parasiticides, grew the company to a cash flow positive position with 85 employees in five years and divested the company to Ceva Animal Health in 2010. A graduate of Indiana University, she has continued her executive training at Harvard, Columbia, University of Chicago and the Wharton School of Business.
Ellen de Brabander
Sven Arnouts
Justine Conway
Lawrence Brown
Dr Lawrence Brown is a Sector Specialist (Animal Sciences & Aquaculture) for the Department for International Trade. His main focus is on inward investment into the UK but also assists with trade. Lawrence is a qualified veterinary surgeon and consultant, working with private and public sector clients through his consultancy company LJB Veterinary Services Ltd. He is an elected member of the British Veterinary Association's (BVA) Scottish Council and is studying for an Executive MBA at the University of Edinburgh.
Ivan Farneti
Ivan has been an active venture capital investor for the last 20 years and he is the co-founder of Five Seasons Ventures, the first European venture fund fully focused on Foodtech.
He is passionate about product and technology innovation aimed at solving big challenges in the food industry: from alternative sources of proteins, to functional foods, from new models of food distribution to the reduction of food waste. At Five Seasons he invested in Tropic Biosciences (plants gene editing), Butternut Box (DNVB pet nutrition), THIS.co (plant-based meat alternatives), Cortilia (D2C fresh food retailer), YFood Labs (balanced meal replacements), Just Spices (D2C spices), Yamo (D2C fresh baby food) and La Fourche (D2C organic groceries).
His experience from previous venture funds in London, includes structuring investments, organizational and strategy development, setting up governance for growth and planning for successful exits. He was an early stage investor in Everbridge, Inc. (Nasdaq: EVBG), Tridion (acq. by SDL Plc), Gomez (acq. by Compuware), among others.
In his spare time he enjoys family life, cooking, fly fishing, and practicing jiu-jitsu with his son Adam.
Karolina Zapadka
Gentiane Gorlier
Richard Casey
Samuel Laing
Jamie Stein
Marcio Kanas
Linda Rhodes
Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.
Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.
Jo Malone
Jo qualified from Glasgow vet school in 1998, she has been actively involved in both clinical and all business aspects of veterinary life throughout her career. Jo has worked for Minster Vets for the last 16 years focusing on small animal clinical practice.
In the last 10 years she has become increasingly involved in managing the practice alongside her clinical role. Being instrumental in growing the practice, improving performance and developing the people within the practice. Jo is passionate about the veterinary profession and the people involved in it.
In 2015 she became Managing Director of VetPartners and then CEO in 2016.
Katrina Hayter
Edward Chandler
Andre Jordao
Andre is an experienced entrepreneur and the CEO of Barkyn, a pet food subscription combining personalised food and telemedicine, growing in multiple European countries.
Cees Jan Hollander
Julie Fitzpatrick
Bradley Ringeisen
Jon Lowe
Jason Johnson
Julie Lawless
Kate Price
Apryle Horbal
Isabelle Delannoy
Christie Chavis
Hayden Montgomery
Laëtitia Gerbe
Robert DiMarzo
Greg Blair
Charlie Barton
Brian Lindsay
Sébastien Huron
Deborah Dullen
Catriona Curtis
Sven Smit
Nicky Deasy
Greg Michel
Bruce Truman
John Kirkpatrick
David Hallas
Dr. Lenore Bacek
Marie-Paul Lachaud
Marie-Paul Lachaud, DVM is Head of Program Management Europe at Aratana Therapeutics. Her responsibilities include coordinating the process leading to regulatory approval by the European Medicines Agency for Aratana’s products targeted at unmet medical needs in cats and dogs.
Prior to joining Aratana, Dr. Lachaud served the veterinary pharmaceutical industry as an experienced consultant, with a specific focus on international drug clinical development.
From 2000 to 2008, Dr. Lachaud was the European animal health director at ICON Clinical Research in Paris, France. In 1990, she co-founded PROTOCOLE, the first European veterinary consultancy and contract research organization focused on drug clinical development and regulatory affairs, which was acquired by ICON in 2000.
Dr. Lachaud has been involved in transitioning human drugs to meet unmet needs in veterinary medicine for years. Her work has resulted in significant animal health product approvals in Europe and the United-States for companion animals in a number of innovative therapeutic areas, including reproduction, chronic heart failure, chronic kidney disease, pain management, oncology and neurobehavioral disorders.
She received her veterinary degree from Alfort National Veterinary School in Paris and her doctorate in veterinary medicine from the University of Paris, France.
Marijn Hendrickx
Matthieu Frechin
Rob Readnour
Dr. Readnour currently serves on or has visitation rights to the following companies: AgTech Accelerator, a unique startup accelerator focused on discovering and developing emerging agricultural technology companies, Skyline Vet Pharma, a company that is developing veterinary pharmaceuticals using proven delivery technologies to reformulate drugs with established animal health markets, and Boragen, a company that is developing small molecule approaches focused on leveraging the unique chemical properties of boron chemistry, both in crop protection and animal health.
Prior to joining MGP, Dr. Readnour worked at Elanco Animal Health for 27 years. During his Elanco tenure, he held several senior management positions in which he was responsible for developing and executing Elanco’s Research and Development strategies for entering several new business areas (companion animal pharmaceuticals, vaccines and enzymes). In 2017, these new business areas accounted for nearly 50% of Elanco’s $3.0 billion in sales. Dr. Readnour played an important role in Elanco’s acquisition and integration of Novartis Animal Health, Lohmann Animal Health, ChemGen and Janssen Animal Health. Within Elanco, Dr. Readnour led several initiatives to transform Research and Development through the piloting of new approaches to developing animal health products. He developed and led Elanco’s new technology scouting, acquisition and due diligence efforts. He pioneered a lean product development model which allowed Elanco to enter new areas of business without significant capital investment. He led initial efforts for Elanco to invest in early stage companies and partner with external funding sources to develop products with minimal initial investment from Elanco. Dr. Readnour served as a member of the Food and Agriculture Section of Bio International Board and as an External Advisory Board member for University of Illinois Animal Science Department.
Prior to entering management in Elanco, Dr. Readnour was an internationally recognized expert on animal health product development, analytical chemistry, human food safety and drug residues with 11 publications and 14 external presentations. Throughout his career, Dr. Readnour was responsible for the development and commercialization of 10 animal health products. Dr. Readnour received his PhD in Analytical Chemistry from University of Illinois in 1990.
Stephen Lesser
Tina Sejersgård Fanø
Rimma Driscoll
Rimma Driscoll is an executive in Global Business Development and Strategic Alliances with 20+ years in the field. Rimma has a depth of experience in a broad range of global transactions including JVs,Strategic Alliances, Collaborations, Acquisitions, Divestitures, Licensing Deals, and Partnerships. This experience span from small Discovery deals to multi-billionaire dollar divestitures. Rimma guides Multi-function teams on the external strategies and then leads all aspects of negotiations, and leverages external relationships to bring transactions to closure. She has worked extensively in Pharmaceuticals, Consumer Healthcare and Consumer Products businesses.
Ben North
Ben holds the position of Director of Portfolio and Innovation Strategy at PHARMAQ, the aquaculture health business of Zoetis. Ben has worked for PHARMAQ since 2008 and held a variety of technical and commercial roles, including 7 years as the Country Manager of PHARMAQ’s UK business. In 2017 Ben moved across full time to PHARMAQ’s Oslo-based R&D organisation as R&D Portfolio Director, before taking on the current role in 2020, which is focused on delivering an overarching innovation strategy across the continuum of care for aquaculture health.
Before joining PHARMAQ, Ben worked as a post-doctorate researcher at the Stirling University, where he also undertook his PhD. The focus of Ben’s research was investigating the impact of husbandry factors such as stocking density and water quality on fish welfare. This research identified operational welfare indicators for fish in commercial aquaculture systems and generated welfare indices by combining a range of objective indicators. Ben also holds a BSc in Marine Biology, an MSc in Aquaculture and in 2018 completed an Executive MBA program at Warwick Business School.
Juan-Carlos Carrillo Peláez
Martin Sutcliffe
Adrienne Woodward
Dr. Kimberly Simmons
Udi Cohen
Ian Tarpey
Laurie Hueneke
Alan Beynon
Aaron Schacht
Prior to this role, Mr. Aaron Schacht was the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Healthheld. Before that, he held the role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.
Chuck Latham
Candise Goodwin
Dr. Ralph Heuser
Andrew Van Kessel
Dr. Jürg Baggenstoss
Sabine Koelle
Dawn Howard
Dr. David Hodges
Piers Hampson
Charles Cosgrave
Peter Michel
Andrea Iucci
Tiffany Wood
Oliver Boucher
Oliver Boucher has a successful track record creating and managing start-ups and executing strategic transactions at Board level on both the buy-side and sell-side of the life science business-to-business (B2B) market within the pharmaceutical and diagnostics industries. He also has significant experience in fund-raising, both dilutive and non-dilutive. He has held senior commercial and business roles in a succession of biotech companies after having gained executive level experience for seven years as a director of business development at GSK. Before joining industry, Oliver Boucher was a patent attorney in London, Montreal and Paris. He received an MA in genetics and molecular biology from Cambridge University and earned an MBA from INSEAD Business School. Mr Boucher joined Zoetis in 2017.
Trine Vatle
Sioned Timothy
Martin Sutherland
Daniella Morgan-Pascualvaca
Mel Munro
Philip Grose
Daniel Golden
Steve Maughan
Paul Casady
Martin Borchert
Almut Hoffman
Jonathan Hunt
Harry Bowcott
Qi Li
Natacha Jamar
James Wright
Robert Jones
Carel du Marchie Sarvaas
Carel du Marchie Sarvaas has been working as a senior government affairs and communications advisor in Brussels and Washington DC for 20 years.
He will move to IFAH from EuropaBio, the Association of Biotechnology Industries, where he has been Director for Agricultural Biotechnology for some 4 years. Prior to EuropaBio, Carel worked at international consultancies and think tanks in Brussels and Washington DC, most often serving clients with science-based policy and communications challenges.
Carel is experienced in the interplay between regulatory, political and communications issues as they relate to science, innovation and policy. A Dutch national, he is married and has four children. He has lived in South Africa, Canada, Brussels, and Paris and holds degrees from the University of Leiden and Johns Hopkins University
be the first to receive the 2024 agenda
Register your interest for 2024!
Fill in the short form and be the first to receive the agenda for Animal Health, Nutrition and Technology Innovation Europe 2024.
Register your Interest
Advisory Board
Robert Kelly
Ellen de Brabander
Author:
Jean-Luc Michel
After graduating from the University of Pharmacy of Lyon with a Doctorate and from EM Lyon Business School with an MBA, Jean-Luc Michel started his career by creating his own consultancy company. He joined the pharmaceutical industry in 1991 spending 10 years developing a solid expertise in consumer healthcare and nutrition. During this period, he held a variety of senior marketing and sales management positions in France at Monsanto (Searle) and at Johnson&Johnson / Merck & Co where he was an Executive Committee member of the French subsidiary.
In 2001, Jean-Luc joined Merial, a leader in the animal health industry, where he held some key senior roles, such as EMEA Marketing Director of the Companion Animal Global Enterprise; Head of Marketing EMEA; Executive Marketing Director (Pet Business) in the US; VP, Head of Pet Vet Business Unit; and in 2016 joined the Executive Committee of Merial as Head of Global Commercial Development.
After the acquisition of Merial by Boehringer Ingelheim, Jean-Luc was appointed Head of Global Companion Animal Strategic Business Unit and became a member of the Executive Committee of the Boehringer Ingelheim Animal Health Business Unit.
Jean-Luc Michel
After graduating from the University of Pharmacy of Lyon with a Doctorate and from EM Lyon Business School with an MBA, Jean-Luc Michel started his career by creating his own consultancy company. He joined the pharmaceutical industry in 1991 spending 10 years developing a solid expertise in consumer healthcare and nutrition. During this period, he held a variety of senior marketing and sales management positions in France at Monsanto (Searle) and at Johnson&Johnson / Merck & Co where he was an Executive Committee member of the French subsidiary.
In 2001, Jean-Luc joined Merial, a leader in the animal health industry, where he held some key senior roles, such as EMEA Marketing Director of the Companion Animal Global Enterprise; Head of Marketing EMEA; Executive Marketing Director (Pet Business) in the US; VP, Head of Pet Vet Business Unit; and in 2016 joined the Executive Committee of Merial as Head of Global Commercial Development.
After the acquisition of Merial by Boehringer Ingelheim, Jean-Luc was appointed Head of Global Companion Animal Strategic Business Unit and became a member of the Executive Committee of the Boehringer Ingelheim Animal Health Business Unit.
Kathy Turner
Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.
Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.
Linda Rhodes
Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.
Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.
Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014. Latterly he has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private equity backed healthcare. Alan holds a Bachelor's degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He is Chair of the BVCA for 2016 – 2017 and previously chaired its Responsible Investment Advisory Board.
Alan Mackay
Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014. Latterly he has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private equity backed healthcare. Alan holds a Bachelor's degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He is Chair of the BVCA for 2016 – 2017 and previously chaired its Responsible Investment Advisory Board.
Thomas Zerzan
Sébastien Huron
Prior to this role, Mr. Aaron Schacht was the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Healthheld. Before that, he held the role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.
Aaron Schacht
Prior to this role, Mr. Aaron Schacht was the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Healthheld. Before that, he held the role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.
Selection Committee
Charles is a healthcare focused investment banker with approximately 20 years’ experience with specialty pharmaceutical companies in the US and Europe. Previously Charles was Managing Director for the international healthcare team at BofA Merrill Lynch and currently leads Commerzbank’s global healthcare team. During this time he has advised multiple companies on public and private capital raises, debt financing, mergers, acquisitions and out-licensing transactions.
He has a particular focus on the veterinary healthcare sector, where he has been involved in transactions for almost all of the top 15 companies in the sector. Recent transactions include advising Virbac on the acquisition of the Sentinel and Sentinel Spectrum brands from Novartis, advising Lohmann Animal Health on its sale to Eli Lilly, advising Pharmaq on Permira’s investment in the company and assisting United Biomedical with creating a global strategic alliance for its swine vaccine portfolio.
Charles also chairs the Commercialisation committee of the London School of Hygiene and Tropical Medicine and serves on the school’s Finance and Planning committee. In addition, he is Chairman of the Bulldog Trust, which funds and supports entrepreneurial charities, and sits on the Boards of Directors of Placehill Limited (growth capital), Laguna Ventures Limited (late stage venture finance) and Atlantic Healthcare plc.
Charles Hoare
Charles is a healthcare focused investment banker with approximately 20 years’ experience with specialty pharmaceutical companies in the US and Europe. Previously Charles was Managing Director for the international healthcare team at BofA Merrill Lynch and currently leads Commerzbank’s global healthcare team. During this time he has advised multiple companies on public and private capital raises, debt financing, mergers, acquisitions and out-licensing transactions.
He has a particular focus on the veterinary healthcare sector, where he has been involved in transactions for almost all of the top 15 companies in the sector. Recent transactions include advising Virbac on the acquisition of the Sentinel and Sentinel Spectrum brands from Novartis, advising Lohmann Animal Health on its sale to Eli Lilly, advising Pharmaq on Permira’s investment in the company and assisting United Biomedical with creating a global strategic alliance for its swine vaccine portfolio.
Charles also chairs the Commercialisation committee of the London School of Hygiene and Tropical Medicine and serves on the school’s Finance and Planning committee. In addition, he is Chairman of the Bulldog Trust, which funds and supports entrepreneurial charities, and sits on the Boards of Directors of Placehill Limited (growth capital), Laguna Ventures Limited (late stage venture finance) and Atlantic Healthcare plc.
Phil Austin
Julia Stephanus is a 30 year veteran of the veterinary pharmaceutical industry. Currently Julia is President of Avviare, a consulting firm specializing in supporting veterinary focused start-ups.
Julia has been involved in the development and launch of 28 veterinary products. She has been a senior executive in two start-up pharmaceutical companies (Aratana Therapeutics and Summit VetPharm), and held key positions at multi-nationals including Pfizer (now Zoetis) and its legacy companies.
As Chief Commercial Officer of Aratana Julia provided the commercial leadership resulting in a successful IPO (NASDAQ:PETX), high-impact corporate branding, innovative go-to-market strategies for five therapeutics and the staffing of the inaugural commercial organization.
As founder and CEO of Summit VetPharm, Julia developed and launched a new line of companion animal parasiticides, grew the company to a cash flow positive position with 85 employees in five years and divested the company to Ceva Animal Health in 2010. A graduate of Indiana University, she has continued her executive training at Harvard, Columbia, University of Chicago and the Wharton School of Business.
Julia Stephanus
Julia Stephanus is a 30 year veteran of the veterinary pharmaceutical industry. Currently Julia is President of Avviare, a consulting firm specializing in supporting veterinary focused start-ups.
Julia has been involved in the development and launch of 28 veterinary products. She has been a senior executive in two start-up pharmaceutical companies (Aratana Therapeutics and Summit VetPharm), and held key positions at multi-nationals including Pfizer (now Zoetis) and its legacy companies.
As Chief Commercial Officer of Aratana Julia provided the commercial leadership resulting in a successful IPO (NASDAQ:PETX), high-impact corporate branding, innovative go-to-market strategies for five therapeutics and the staffing of the inaugural commercial organization.
As founder and CEO of Summit VetPharm, Julia developed and launched a new line of companion animal parasiticides, grew the company to a cash flow positive position with 85 employees in five years and divested the company to Ceva Animal Health in 2010. A graduate of Indiana University, she has continued her executive training at Harvard, Columbia, University of Chicago and the Wharton School of Business.
Dr. Cindy Cole is a Technical Partner at Digitalis Ventures and an Associate Clinical Professor at the University of Florida. Prior to joining Digitalis she was in the animal health industry for many years holding senior leadership and R&D roles at Mars Petcare, Novartis Animal Health, IDEXX, and Piedmont Pharmaceuticals. Dr. Cole completed her DVM and PhD at the University of Florida and was on the faculty of the University of California, Davis and UF.
Cindy Cole
Dr. Cindy Cole is a Technical Partner at Digitalis Ventures and an Associate Clinical Professor at the University of Florida. Prior to joining Digitalis she was in the animal health industry for many years holding senior leadership and R&D roles at Mars Petcare, Novartis Animal Health, IDEXX, and Piedmont Pharmaceuticals. Dr. Cole completed her DVM and PhD at the University of Florida and was on the faculty of the University of California, Davis and UF.
Jason Scott
Dr Paul Dick D.V.M. M.Sc. obtained his veterinary medical degree with honours in 1984.
While working in clinical practice he completed his Masters in Immunology and Virology transitioning into the Pharmaceutical industry in 1988. Dr. Dick has over 25 years experience in the pharmaceutical space including general management and leadership roles, business development, commercialization, regulatory affairs, and product development encompassing medicinal, non-medicinal and natural health products.
His work in this sector has ranged from small “start up” companies to medium and large multi-nationals functioning in various capacities from research to COO and CEO.
Dr. Dick has worked extensively with Health Canada and the Canadian Food Inspection Agency on numerous regulatory submissions and on several Departmental Committees.
In addition he has been a recipient of the NSERC Synergy Award and has served as a peer reviewer of NSERC strategic grants. He is currently heading his own consulting firm ( Paul Dick and Associates Ltd.) and is the managing partner and president of a venture capital partnership (Vet Venture Capital Inc.).
Paul Dick
Dr Paul Dick D.V.M. M.Sc. obtained his veterinary medical degree with honours in 1984.
While working in clinical practice he completed his Masters in Immunology and Virology transitioning into the Pharmaceutical industry in 1988. Dr. Dick has over 25 years experience in the pharmaceutical space including general management and leadership roles, business development, commercialization, regulatory affairs, and product development encompassing medicinal, non-medicinal and natural health products.
His work in this sector has ranged from small “start up” companies to medium and large multi-nationals functioning in various capacities from research to COO and CEO.
Dr. Dick has worked extensively with Health Canada and the Canadian Food Inspection Agency on numerous regulatory submissions and on several Departmental Committees.
In addition he has been a recipient of the NSERC Synergy Award and has served as a peer reviewer of NSERC strategic grants. He is currently heading his own consulting firm ( Paul Dick and Associates Ltd.) and is the managing partner and president of a venture capital partnership (Vet Venture Capital Inc.).
Tom manages the process of screening new business opportunities for Aqua-Spark and negotiating new investments. He has been directly involved throughout the investment process for the majority of the current Aqua-Spark portfolio, ranging from investments in feed ingredients, technology, health, genetics and production. Tom joined Aqua-Spark in 2015. Prior to Aqua-Spark, he worked in the Gulf region with the Netherlands Agricultural Attaché for GCC countries and the Netherlands Embassy in the Sultanate of Oman, where he conducted research on the development of local aquaculture industry. He has also spearheaded transnational events to elevate public and private dialogue on emerging opportunities in aquaculture. Tom received a Master in Business Geography from Utrecht University. A fervent surfer, Tom is dedicated to conserving the ocean for future generations.
Tom Prins
Tom manages the process of screening new business opportunities for Aqua-Spark and negotiating new investments. He has been directly involved throughout the investment process for the majority of the current Aqua-Spark portfolio, ranging from investments in feed ingredients, technology, health, genetics and production. Tom joined Aqua-Spark in 2015. Prior to Aqua-Spark, he worked in the Gulf region with the Netherlands Agricultural Attaché for GCC countries and the Netherlands Embassy in the Sultanate of Oman, where he conducted research on the development of local aquaculture industry. He has also spearheaded transnational events to elevate public and private dialogue on emerging opportunities in aquaculture. Tom received a Master in Business Geography from Utrecht University. A fervent surfer, Tom is dedicated to conserving the ocean for future generations.
Karolina Zapadka
Gentiane Gorlier
Jamie Stein
John McNicol
2023 Partners
Animal Health Innovation Europe is supported by the most influential bodies across the Animal Health, Nutrition and Veterinary industries.
Be one of them, communicate about the event to your network, spread the word and become a Supporter of the Animal Health, Nutrition and Technology Innovation series.
Headline Partner
Zoetis
Website: https://www.zoetis.com/
Website: www.zoetis.com
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2019, the company generated annual revenue of $6.3 billion with approximately 10,600 employees.
For more information, visit www.zoetis.com.
Platinum Associate Partners
Elanco
Website: www.elanco.com
Elanco Animal Health (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we’re driven by our vision of Food and Companionship Enriching life and our Elanco Healthy Purpose™ CSR framework – all to advance the health of animals, people and the planet.
MSD Animal Health
Website: https://www.msd-animal-health.com/
For more than a century, Merck, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is the global animal health business unit of Merck.
Through its commitment to the Science of Healthier Animals®, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services.
Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com or connect with us on LinkedIn, Facebook and Twitter at @MSDAnimalHealth.
IDEXX
Website: www.idexx.com
IDEXX Laboratories, Inc. is a member of the S&P 500® Index and is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency, and build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for livestock and poultry, and testing for the quality and safety of water and milk. Headquartered in Maine, IDEXX employs more than 8,000 people and offers products to customers in over 175 countries.
Our purpose is to be a great company that creates exceptional long-term value for our customers, employees, and shareholders by enhancing the health and well-being of pets, people, and livestock.
For more information about IDEXX, visit: www.idexx.com
Associate Partners
Provaxs - Ghent University
Website: https://www.provaxs.com/
Provaxs is Ghent University’s Business Development Center and industrial liaison for innovation in animal health.
We can become your preferred academic partner and support your innovation-projects in animal health. We combine scientific expertise, knowledge and know-how on animal health with an entrepreneurial organisation of scientists and experienced tech-transfer professionals. Not only that, but thanks to the Industrial Research Fund of Ghent University we have access to proof-of-concept funding, open for collaboration with industry.
GHO Capital
Website: ghocapital.com
Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London. We apply global capabilities and perspectives to unlock high growth healthcare opportunities, targeting Pan-European and transatlantic internationalisation to build market leading businesses of strategic global value. Our proven investment track record reflects the unrivalled depth of our industry expertise and network. We partner with strong management teams to generate long-term sustainable value, improving the efficiency of healthcare delivery to enable better, faster, more accessible healthcare. For further information, please visit www.ghocapital.com.
knoell
Website: https://www.knoell.com/en/markets/animal-health
knoell is the only knowledge-based animal health consultancy and clinical studies specialist with its own technical staff based on three continents: North America, Europe, and Asia. This means easy access and broad reach for you as our valued client into the animal health market. It also benefits you by avoiding duplication, providing a better return on investment for valuable data, improving control of expenditure, and reducing administration.
With the arrival of the two well-known and established brands Cyton and Triveritas in the knoell group, knoell was able to expand their business into the animal health market. Both companies have more than two decades of experience in the animal health market in Europe and the USA. The joint activities led to growth of the animal health business in Europe, the US and Asia as well. In order to strengthen its presence in the USA, knoell Animal Health LLC was founded in early 2020. Since February 2021, Triveritas operates as knoell Animal Health Ltd.
With animal health experts working in the US, Europe and Asia and an established network of trusted partners, knoell can support clients' business aspirations better than ever before and provide a truly global service.
Our animal health team offers a full portfolio of services, including start-to-finish product development and ad hoc services.
Argenta
Website: https://www.argentaglobal.com/
About Argenta™
Founded in New Zealand, Argenta’s talented and committed employees are dedicated to delivering excellence in animal health to customers around the world. With research and/or GMP manufacturing operations in Germany (KLIFOVET), New Zealand, Spain (Pen & Tec Consulting), the United Kingdom, and the United States, Argenta holds a unique position as the only combined global contract research organisation (CRO) and contract development and manufacturing organisation (CDMO) specialising in animal health.
Argenta operates from Molecule to Market in partnership with customers of all sizes from all corners of the world, supporting their research and development, clinical research, regulatory, scale-up and manufacturing needs along the veterinary product development journey.
The day-to-day ethos that drives Argenta forward is a mission focused on global partnerships, a Molecule to Market approach, and innovation. At the core of the business and the organisation is collaboration – among the global employee base and with their customers.
Argenta proudly partners with a vast range of global customers. Our services and facilities scale to meet the requirements of the largest multinationals, whilst, at the other end of the spectrum, offering start-ups and small companies capabilities and solutions that help bring their ideas to fruition.
For more information, please visit www.argentaglobal.com
Syngene
Website: www.syngeneintl.com
Syngene International Ltd. is an innovation focused global discovery, development and manufacturing organisation providing integrated scientific services to the pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical industries around the world. Syngene’s clientele include world leaders such as Bristol-Myers Squibb, Baxter, Amgen, GSK, Merck KGaA and Herbalife. Its innovative culture is driven by the passion of its 4000- strong team of scientists who work with clients from around the world to solve their scientific problems, improve R&D productivity, speedup time to market and lower the cost of innovation. For more details, visit www.syngeneintl.com.
Vetoquinol
Website: www.vetoquinol.co.uk
Founded in 1933, Vetoquinol is the 9th largest veterinary pharmaceutical business, committed to the protection and well-being of both animals and people.
Siemens Healthineers
Website: https://www.siemens-healthineers.com/
Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) pioneers breakthroughs in healthcare. For everyone. Everywhere. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers and its regional companies is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care. In fiscal 2021, which ended on September 30, 2021, Siemens Healthineers, which has approximately 66,000 employees worldwide, generated revenue of €18.0 billion and adjusted EBIT of €3.1 billion. Further information is available at www.siemens-healthineers.com.
Start-up Development Partner
Paul Dick and Associates
Website: https://pauldickassociates.com/
Paul Dick & Associates Ltd (PDA) was created in 2010 to meet the needs of large, medium and small animal health companies wishing to develop and commercialize new technologies and products. In 2017, PDA expanded into the human health space to offer its services to companies developing new technologies and services for the human health market.
PDA has a highly experienced team that, in combination with other partner organizations (Contract Research Organizations, Contract Development/ Manufacturing Organizations, Veterinary Colleges, Private Research Facilities), makes for a best in class Human and Animal Health consulting firm.
Knowledge Partner
McKinsey & Company
Website: https://www.mckinsey.com/
There was a time when economic growth, sustainability, and inclusion were seen as trade-offs, but leaders today need to achieve all three. This new paradigm of growth will be more sustainable, driving innovation while reducing environmental impact. It will also be more inclusive, creating access to opportunities for people worldwide.
This is not an easy task, but McKinsey & Company's ambition is to help organizations and their leaders make it a reality. They combine bold strategies and transformative technologies to help organizations innovate more sustainably, achieve lasting gains in performance, and build workforces that will thrive for this generation and the next.
Consulting Partner
Stonehaven Consulting
Website: https://www.stonehaven-consulting.com/
Senior Event Partner
Boehringer Ingelheim
Website: www.boehringer-ingelheim.com
Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates presently with a total of some 50,000 employees worldwide. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of net sales.
For more information, please visit www.Boehringer-Ingleheim.com
Axiota Animal Health
Website: https://axiota.com/
Axiota® delivers best-in-class animal health products with proven modes of action that help manage risk and support cattle health, performance, and well-being across all stages of beef and dairy production.
The Axiota portfolio includes MULTIMIN® 90 and Lactipro®.
MULTIMIN® 90 is a prescription-only injectable trace mineral that provides a supplemental source of zinc, selenium, copper and manganese. Trace minerals are the building blocks of the immune and reproductive systems and MULTIMIN® 90 provides sure trace mineral supply by timed injection.
Lactipro® supplies an immediate, viable population of Mega e® – a prolific, rumen-native microbe that preferentially consumes lactic acid and produces butyrate.
MULTIMIN® 90 and Lactipro® both prepare cattle to thrive during transition and stress.
United Animal Health
Website: http://www.unitedanh.com/
United Animal Health, formally JBS United, was founded in 1956 and is dedicated to providing research based solutions that create value for its partners in animal agriculture. United Animal Health offers livestock nutrition and health products globally through the United Animal Health or affiliate brands. The company, originally known as United Feeds, set itself apart from the competition by intimately getting to know customers and understanding what they needed to be more successful. That guiding principle has been the foundation as United Animal Health has grown from that one room office company to an organization employing over 340 individuals.
Lawless Strategic Communications
Website: www.lawlesscomms.com
At Lawless Strategic Communications, we're your Corporate Communications experts. With decades of success leading Corporate Communications at top-tier public and private companies, Julie Lawless launched Lawless Strategic Communications in 2022, bringing the Purpose + Passion approach to serve companies in animal health and nutrition, veterinary and food production sectors. From the most complex reputational and brand issues to routine transaction communications, thought leadership, internal engagement and ESG programs, our knowledge and expertise can produce significant results. We understand the industry and quickly work alongside you to enhance and protect your vision - always grounded in your strategy and Purpose. Visit us today to learn more about our approach and how we can help you at www.lawlesscomms.com.
DKP Consulting
Website: https://drkateprice.com/
Dr. Kate Price partners with you to understand the complexities of your organization and leadership, delving into the neuropsychology of human behavior to design simple, evidence-based solutions to optimize your business results and transform your culture. Trained as a clinical psychologist, Dr. Kate brings the depth of knowledge and expertise you need to make impactful and sustainable changes within your organization—and yourself, because all change begins with the individual.
Clinglobal
Website: https://www.clinglobal.com/
CLINGLOBAL is an Animal Health Services company established during 2016 in Mauritius acting as a contract holding and centralised service provider for the ever expanding “Clin” group of companies.
Our unique business model allows the animal health industry and community to benefit from our simplified contracting solutions by having a customizable all-inclusive approach and the delivery of animal health research projects and services.
Novozymes
Website: https://www.novozymes.com/en
Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions.
Event Partner
BiomEdit
Website: https://www.biomedit.com/
BiomEdit is a microbiome innovation company that discovers, designs and develops novel probiotics, microbiome derived bioactives and engineered microbial medicines to address unmet needs in animal health. We partner with Ginkgo Bioworks to amplify and accelerate product discovery and development with a goal of introducing breakthrough innovation for livestock producers and veterinarians.
ZENOAQ
Website: http://www.zenoaq.jp/english/index.html
ZENOAQ aims to create a shared and everlasting future for humans and animals. Amidst efforts to improve drug development, veterinary therapy and biotechnology, ZENOAQ strives to enhance the value of animals. The core activities in ZENOAQ are deeply connected with our customers, which in turn, affects their animals in many different ways. These connections form a network that is not just limited to Japan, but is something that will also reach across international borders, creating mutual benefit for both humans and animals in the future.
Bonaccord
Website: https://www.bonaccord.law/
Bonaccord is an award winning law firm established to support the scientific community. They help innovative businesses maximise the commercial value of their technologies and have particular expertise in the life sciences, specialty chemicals and advanced engineering.
Vetio Animal Health
Website: https://vetio.com/
As a Contract Development and Manufacturing Organization (CDMO) dedicated to Animal Health, Vetio integrates product development, analytical services, technical services, and commercial manufacturing of veterinary pharmaceuticals using a Quality-by-Design approach. Vetio is your single-source partner for successful product approval, scale-up, and ongoing commercial supply.
Vetio has provided expertise to animal health companies around the world since 2001 and is committed to the development and manufacturing of products that improve the lives of animals, while assuring the safety, quality and compliance of our products to the highest industry standards.
Ask Us about our intellectual property in pharmaceutical soft chews and palatability. Please visit www.vetio.com and watch our brief company overview video.
Pet Flavors
Website: https://www.petflavors.com/
PF, Inc. (Pet Flavors, Inc.) is the world leading developer and manufacturer of quality flavor bases for both pharmaceutical drugs and nutritional supplements in the animal health industry. PF Inc. sells several types of flavor bases for use in formulating palatable canine, feline, and equine dosage forms that are sold on a worldwide basis. PF’s Artificial Powdered Beef Flavor; PC-0125 is sold to 9 of the top 10 largest animal health pharmaceutical companies in the world and has been successfully formulated in over 20 New Animal Drug Approvals (NADAs). Our company has over 30 years of experience with formulation and product development. With an active ingredient and our flavor bases we can create highly palatable chewable tablets, soft chews or granules. Our services include improving the palatability of an existing product, creating product line extensions or developing entirely new products. Please visit our website www.petflavors.com for detailed information.
Aenova
Website: https://www.aenova-group.com/en/home
The Aenova Group is a leading global contract manufacturer and development service provider for the pharmaceutical and healthcare industries. As a full-service provider, Aenova develops, produces and packages all common dosage forms, product groups and active ingredient classes of pharmaceuticals and food supplements for human and animal health: solid, semi-solid and liquid, sterile and non-sterile, high and low dose, OEB 1-5, and Fill&Finish of biologics/vaccines up to BSL-2. Around 4,100 employees at 16 locations in Europe and the USA contribute to the company's success.
Dômes Pharma
Website: https://www.domespharma.com/?lang=en
Dômes Pharma is an independent, family-owned company that has been active in the pharmaceutical industry since 1947. It employs 400 people in France, England, Germany, Spain and the USA and has a consolidated turnover of 85 million euros.
For over 70 years, the Group has been developing, manufacturing and marketing solutions for the health and well-being of pets. Through its subsidiaries, the Dômes Pharma Group has 3 complementary areas of expertise that integrate the entire value chain of medicine and cover all distribution channels.
Because humans, animals and the environment are linked by nature, taking care of the animals that share our daily lives means preserving everyone’s health.
Phibro Animal Health Corporation
Website: www.pahc.com
Phibro Animal Health Corporation is one of the leading animal health companies in the world and is dedicated to helping meet the growing demand for animal protein. We are a global diversified animal health and mineral nutrition company. We concentrate exclusively on animals for food production and are one of the few global companies offering a comprehensive range of animal health and mineral nutrition products. For nearly 40 years we have been committed to providing livestock producers with value-based products and solutions to help them maintain and enhance the health of their animals. We develop, manufacture and market a broad range of products for food animals including poultry, swine, beef and dairy cattle and aquaculture. Our products help prevent, control and treat diseases, enhance nutrition to help improve health and contribute to balanced mineral nutrition.
The Department for International Trade (DIT)
Website: https://www.great.gov.uk/
The Department for International Trade (DIT) helps businesses export and grow into global markets. We also help overseas companies locate and grow in the UK - our services are provided in over 100 markets throughout the world.
We secure UK and global prosperity by promoting and financing international trade and investment, and championing free trade.
We are an international economic department, responsible for:
- bringing together policy, promotion and financial expertise to break down barriers to trade and investment, and help businesses succeed
- delivering a new trade policy framework for the UK as we leave the EU
- promoting British trade and investment across the world
- building the global appetite for British goods and services
Zomedica
Website: https://zomedica.com/
Zomedica is an animal health company focused on meeting the needs of clinical veterinarians in ways that promote both patient and practice health. Our mission is to advance the effectiveness and financial well-being of veterinary practitioners by delivering professionally beneficial diagnostic products and services.
Magnawave
Website: https://magnawavepemf.com/
MagnaWave has been working with PEMF (Pulsed Electro-Magnetic Fields) equipment for 15 years. We are proudly family owned and operated. All of our products are made in the United States and are third-party tested for safe and secure operation. We stand behind our machines with our 3-year, full coverage warranty and additional 7-year guarantee that you will never spend more than $700 in a calendar year to repair your machine.
APHA Scientific
Website: www.aphascientific.com
Animal and Plant Health Agency (APHA) are an internationally recognised centre of scientific excellence providing a wide range of research and consultancy to the UK Government and commercial customers. We specialise in diseases of livestock and plants, diagnosis of disease and surveillance of new and emerging disease. APHA has achieved world reference laboratory status for a number of animal diseases.
To enhance its scientific activity APHA develops commercial products and services and makes them available to organisations globally. These are brought together under APHA Scientific to ensure the products and services are delivered effectively to customers.
Our products and services include:
- Biological reagents and test kits
- Proficiency testing (VETQAS)
- Wildlife management and radar detection
- Laboratory testing
- Vaccine development and testing
- Virus discovery
- Pathology and bio-imaging
- Bacterial identification and characterisation
- Veterinary research and development
- Access to Animal and Plant Health Agency intellectual property.
For more information about any of our services please contact
T: 03000 600001
E: [email protected]
www.aphascientific.com
AB7 Sante
Website: https://www.ab7group.com/en/home
AB7 Santé is a French Veterinary Pharmaceutical Laboratory that has been innovating for over 50 years in the field of Animal Health.
Fully integrated for better agility, AB7 is specialized in research, development, production, quality control, registration and sales of veterinary medicines, generics, OTC, biocides & pet care products for the global market.
With its industrial know-how over 2 certified units in France (GMP) and in the United States (EPA), AB7 is able to address specific manufacturing needs, from small series to large volumes, by ensuring a high level of quality and offering the capacity to adapt manufacturing resources, method and technology.
As a CDMO Company, we offer our partners pharmaceutical and non-pharmaceutical outsourcing activities from development to manufacturing by integrating an innovative, sustainable and responsible approach.
AB7 has continually invested in R&D and production capacities with a constant desire to develop its industrial know-how and to own state-of-the-art equipment for a relevant service in the field of pharmaceutical products within GMP standards. Our 5 R&D Laboratories with more than 45 specialists and our industrial equipments allow us to satisfy the requirements of both small and large pharmaceutical companies within a constructive partnership.
Specialized in exclusive drug delivery systems, AB7 supports its partners in the development of new innovative products and is able to provide full line of products with more traditional galenics.
At AB7, we aim to contribute to today's animal health and welfare challenges by working with international partners to achieve this mission together.
Tofflon
Website: http://www.tofflon.com/en/index.html
Tofflon science and technology group is a comprehensive pharmaceutical equipment manufacturer. We provide a wide range of core equipment, integrated systems, process support and pharma engineering for the pharma, and biotech industries.
Found in 1993, Tofflon has supplied more than 10,000 equipment and systems for 2,500+ pharmaceutical companies in over 45 countries and regions around the world specializing in the field of liquid and lyo injectables, chemical API, bioengineering and pharma packaging, etc.
Tofflon has been expanding in Europe since 2007. We have established a business hub in Bergamo Italy to offer professional and rapid technical support and service for European customers.
For more information please visit: http://www.tofflon.com/en/index.html
Bioceltix
Website: https://bioceltix.com/en/
At Bioceltix, we are pursuing three flagship programs with global potential – two medicines for dogs (osteoarthrosis and atopic dermatitis) and one for horses suffering from arthritis. We use the original ALLO-BCLX technology focused on allogeneic approach that allows stem cells derived from a small number of healthy donors to be administered to a large number of patients, and thus in the form of a therapeutic product. We develop biological drugs which, in addition to symptomatic action, should have a causal effect by influencing the inflammatory environment and activating the natural reconstruction mechanisms of pathologically changed tissues. As a result, our future drugs will have fewer side effects and work long-term after a single administration. Our technology is fully scalable and allows for the serial production of drugs. In addition, we have a GMP-standard manufacturing facility, which enables us to carry out projects quickly and independently of subcontractors.
Agri-EPI Centre
Website: www.agri-epicentre.com
Agri-EPI is the centre for Engineering Precision Innovation in farming, aiming to revolutionise farming & food systems through precision technology.
We are a partner of choice for agri-tech developers from start-ups through to established companies. We have delivered over 100 commercial & 45 collaborative R&D agri-tech projects. Agri-EPI helps to develop profitable and productive solutions to empower more sustainable farms.
Shell
Website: https://www.shell.com/
Shell’s Powering Progress sets out plans to accelerate the transition of our business to net-zero emissions with a customer-first strategy.
Our gas-to-liquids (GTL) technology turns natural gas into high-quality liquid products usually made from oil. It is founded on more than 45 years of research, development and commercial experience.
Shell Ondina X is a range of next-generation GTL adjuvant oils are mineral-oil-free. The range offers a good alternative to conventional adjuvant oils for formulating high-performance animal vaccines with unique paraffinic structures that provide exceptional purity which are safer for the animal, humans and the ecosystem whilst being scalable and versatile in colder climates.
Transpharmation
Website: https://www.transpharmation.com/
Transpharmation is an in vivo contract research organization focused on therapeutic discovery and lead selection in both the central nervous system and the animal health spaces. Recognised by scientists worldwide for research that delivers life-changing medicines, foods, nutraceuticals, and devices to improve health of humans and companion animals. Improving health through science will always remain our passion. Our clients benefit from decades of experience in cross-species and cross-therapeutic translational biology across our preclinical services. From early PK and safety through proof of concept in indications related to neurology, neuropsychiatry, behaviour, metabolic disease, dermatology and health span, Transpharmation is the go-to collaborator for preclinical success.
Brakke Consulting
Website: https://brakkeconsulting.com/
Brakke Consulting is the most experienced management consulting firm serving the worldwide animal health, nutrition, and related industries. Headquartered in Greensboro, NC, the firm also maintains offices in Bedminster, NJ, Chicago, IL, Dallas, TX, Fort Collins, Co, Houston, TX, Kansas City, MO, Manhattan, KS, Omaha, NE, Pensacola, FL, St. Louis, MO, and Wichita, KS, and has affiliate offices in Osaka and Tokyo.
Our mission is to help each client achieve its business goals, quickly and profitably, through highly knowledgeable and professional management counsel that is firmly rooted in objectivity, imaginativeness, integrity, and sound business principles.
Established in 1986, Brakke provides a full range of consulting services, including General Consulting, Strategic Planning, Mergers and Acquisitions, Market Research Studies, Technology Licensing, Communications Strategies and New Business Development.
Brakke Consulting is also the recognized leader in industry information. Each year, Brakke develops a comprehensive overview presentation on the global animal health and nutrition industries. The firm annually publishes directories of animal health companies and ethical veterinary distributors, plus several syndicated market studies.
The Brakke Consulting team is unique in that it brings together highly talented individuals who have significant CEO or division management experience. These are industry leaders who have built successful businesses, negotiated major acquisitions and divestitures, developed technology, and brought to market some of the most successful products in the industry.
Brakke consultants know the industry, the companies, the executives, the scientists, the technology, the distribution systems, the customers – firsthand.
When you select Brakke Consulting, you engage a resource for your company and your management team that is unmatched in knowledge, expertise, and experience in your industry.
Royal Canin
Website: https://www.royalcanin.com/uk
The Royal Canin company, the owner of the ROYAL CANIN® brand, is a division of Mars Petcare and the global leader in nutritional health for cats and dogs. For over 50 years, Royal Canin has been committed to providing Health Through Nutrition to cats and dogs while improving the quality of their lives.
Founded in 1968 by the French veterinarian Dr. Jean Cathary, Royal Canin has been continually working and partnering with nutritionists, breeders, and veterinarians around the world. Based in Aimargues, in the south of France, we are proudly operating in more than 100 markets with 8,000 Associates all over the globe united by the same purpose.
Our mission is to transform the health and well-being of each cat and dog by pushing the limits of nutrition and knowledge in partnership with pet professionals. Our unique approach always places cats and dogs at the heart of the innovation process. We believe pets make our world better, therefore we are dedicated to achieve our purpose: A BETTER WORLD FOR PETS.
Their age, lifestyle, size, breed, and activity level are observed through science in order to produce specific diets for each animal’s specific needs. Carefully curated nutritional products and tailored formulas are available at pet specialty retailers and veterinary hospitals worldwide.
Become a partner
Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.
With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.
Find out more by calling us at +44 (0)20 3696 2920, email Stephen Swarray at [email protected], Harrison Sharp at [email protected] or downloading our agenda and clicking the "Interested in Sponsorship" box.
Press Partnerships
Whether you are an association, embassy, industry body or publication, we can offer a tailored marketing partnership to suit your needs. As a Media Partner we can:
- Promote your organisation as an event partner across all conference materials, including the website, brochure, emails and on-site programme
- Offer your members or readers a discount on their registration fee for Animal Health Investment Europe
- Provide one free press pass to attend
- Distribute promotional materials at the conference
If you are a registered industry journalist or member of the press and would like to arrange an interview with a speaker or to discuss the event please contact:
Sarah Rowlands
Marketing Director
E: sarah.rowlands@kisacoresearch.com
Photo Gallery
View photos of Animal Health, Nutrition and Technology Innovation events over the years! View the full photo gallery here.
Venue
155 Bishopsgate, London EC2M 3YD
Join us in 2023 at etc. venues, 155 Bishopsgate, London EC2M 3YD
Find nearby hotels here: https://HotelMap.com/MKZ5V
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
Registration ends in
- Please note that a £49 processing fee will apply to any invoices requested.
- Any questions about your registration, please call +44 (0)20 3696 2920 or email us at [email protected].
- All Prices are in GBP
- All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
- No discounts or offers can be combined.
- Please view our Cancellation Policy.
- Emerging Companies are defined as early to mid-stage animal health pharmaceutical or biotech companies that are actively seeking financial investment or product licensing/acquisition. They must be engaged with this company on a full time basis. Those offering consultancy or market intelligence services do not qualify for this rate.
- Please Note: No additional discounts are available on ‘Emerging Company’ pricing.
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.
